Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Gene Expression Assays

May 16, 2011 11:22 am | Product Releases | Comments

Fluidigm Corporation announced the availability of the DELTAgene Assays (gene expression), SNPtype Assays (SNP genotyping), and Access Array Target-specific Primers (target enrichment for next-generation sequencing).


Ultrasonic Coating System

May 16, 2011 11:16 am | Product Releases | Comments

The ExactaCoat XYZ motion ultrasonic coating system from Sono-Tek Corporation is ideal for spraying medical device components such as pacemakers, diagnostic leads, or any small medical device requiring targeted coating of anti-microbials or other solutions.


arGEN-X Moves ARGX-110 Forward in Development

May 16, 2011 11:07 am | News | Comments

arGEN-X announces that it has progressed ARGX-110, its second therapeutic candidate, into formal pre-clinical development. ARGX-110 has potential to improve treatment of autoimmune disorders, inflammation, and cancer.


Otsuka Depression Trial Meets Primary Endpoint

May 16, 2011 11:02 am | News | Comments

Otsuka Pharmaceutical Co., Ltd. announced that a Phase 2 trial of OPC-34712, showed that patients demonstrated improvement in the Montgomery Åsberg Depression Rating Scale Total Score.


FDA Gives Nod to Perrigo Generic

May 16, 2011 10:55 am | News | Comments

Perrigo Company announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for over-the-counter Ranitidine 150, a generic version of Zantac 150.


PerkinElmer Buys Labtronics

May 16, 2011 10:53 am | News | Comments

PerkinElmer, Inc. announced that it has acquired Labtronics Inc., an leader in providing procedures-based electronic laboratory notebook solutions for laboratories performing routine analysis in multiple industries.


Merck Wraps Up Inspire Acquisition

May 16, 2011 10:44 am | News | Comments

Merck & Co. said it completed its $430 million purchase of eye-drug maker Inspire Pharmaceuticals Inc. In the deal, Merck gets Inspire's drug Azasite, which is used to treat pink eye caused by bacteria.


Mylan Selling Generic Xibrom

May 16, 2011 10:40 am | News | Comments

Mylan Inc. said it is now selling a generic version of Xibrom eye drops, which were discontinued in February by their original maker, ISTA Pharmaceuticals Inc.


Teva Buys $460M Stake in Taiyo

May 16, 2011 10:39 am | News | Comments

Teva Pharmaceutical Industries Ltd. said it will pay $460 million to acquire a majority stake in Japanese generic drugmaker Taiyo Pharmaceutical Industry Co., and said it expects its annual sales in Japan to reach $1 billion in the next few years.


Amylin Suing Lilly Over Broken Deal

May 16, 2011 10:36 am | by Tom Murphy | News | Comments

Amylin Pharmaceuticals Inc. filed a lawsuit against Eli Lilly and Co., accusing the larger drugmaker of breaking their commercialization deal for diabetes drugs by teaming with Boehringer Ingelheim to develop and sell a competing product.


Leukemia Society Supports Multiple Myeloma Trial

May 16, 2011 8:32 am | News | Comments

The Leukemia & Lymphoma Society (LLS) and Acetylon Pharmaceuticals announced a business alliance to jointly support a Phase I/II clinical trial of Acetylon’s HDAC6 inhibitor drug candidate, ACY-1215, in multiple myeloma.


Astellas Pharma, BioFocus Collaborate on CNS Target Discovery

May 16, 2011 8:23 am | News | Comments

BioFocus has signed a collaboration agreement with Astellas Pharma Inc. focused on discovering novel targets in the field of CNS disorders.


New Class of Compounds Block Serine Hydrolases

May 16, 2011 8:17 am | News | Comments

Scientists from The Scripps Research Institute have identified a class of compounds that powerfully and selectively block the activity of a large and diverse group of enzymes known as serine hydrolases.. Previously discovered serine hydrolase-blocking compounds have been turned into drugs to treat obesity, diabetes, and Alzheimer’s disease, and are currently in testing as treatments for pain, anxiety, and depression.


Anti-flu virus Proteins Designed via Computational Methods

May 16, 2011 8:10 am | News | Comments

Researchers at the University of Washington have demonstrated the use of computational methods to design new antiviral proteins capable of targeting specific surfaces of flu virus molecules.


Teijin Pharma to Launch Feburic

May 16, 2011 7:51 am | News | Comments

Teijin Pharma Limited will launch Feburic (febuxostat, TMX-67), for treating hyperuricemia in Japan on May 17.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.